These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27792298)

  • 41. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
    Chapple CR; Kaplan SA; Mitcheson D; Klecka J; Cummings J; Drogendijk T; Dorrepaal C; Martin N
    Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
    Cardozo L; Amarenco G; Pushkar D; Mikulas J; Drogendijk T; Wright M; Compion G;
    BJU Int; 2013 May; 111(5):804-10. PubMed ID: 23294801
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement?
    Cardozo L; Khullar V; Wang JT; Guan Z; Sand PK
    BJU Int; 2010 Sep; 106(6):816-21. PubMed ID: 20151972
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder.
    Park C; Park J; Choo MS; Kim JC; Lee JG; Lee JZ; Lee KS; Kim DY; Lee SJ; Seo JT
    Int J Clin Pract; 2014 Feb; 68(2):188-96. PubMed ID: 24373019
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
    Chapple C; Van Kerrebroeck P; Tubaro A; Haag-Molkenteller C; Forst HT; Massow U; Wang J; Brodsky M
    Eur Urol; 2007 Oct; 52(4):1204-12. PubMed ID: 17651893
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia.
    Rackley R; Weiss JP; Rovner ES; Wang JT; Guan Z;
    Urology; 2006 Apr; 67(4):731-6; discussion 736. PubMed ID: 16618562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Solifenacin succinate for the treatment of symptoms of overactive bladder.
    Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
    Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis.
    Abrams P; Swift S
    Eur Urol; 2005 Sep; 48(3):483-7. PubMed ID: 16005564
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
    Marschall-Kehrel D; Feustel C; Persson de Geeter C; Stehr M; Radmayr C; Sillén U; Strugala G
    Eur Urol; 2009 Mar; 55(3):729-36. PubMed ID: 18502028
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle.
    Dokmeci F; Cetinkaya SE; Seval MM; Dai O
    Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():126-131. PubMed ID: 28355584
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
    Kaplan SA; Roehrborn CG; Dmochowski R; Rovner ES; Wang JT; Guan Z
    Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Correlation between psychological stress levels and the severity of overactive bladder symptoms.
    Lai H; Gardner V; Vetter J; Andriole GL
    BMC Urol; 2015 Mar; 15():14. PubMed ID: 25887525
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative Effectiveness of Anticholinergic Therapy for Overactive Bladder in Women: A Systematic Review and Meta-analysis.
    Reynolds WS; McPheeters M; Blume J; Surawicz T; Worley K; Wang L; Hartmann K
    Obstet Gynecol; 2015 Jun; 125(6):1423-1432. PubMed ID: 26000514
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of fesoterodine over 24 hours in subjects with overactive bladder.
    Staskin D; Michel MC; Nitti V; Morrow JD; Wang J; Guan Z
    Curr Med Res Opin; 2010 Apr; 26(4):813-8. PubMed ID: 20121659
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis.
    Mostafaei H; Janisch F; Mori K; Quhal F; Pradere B; Hajebrahimi S; Roehrborn CG; Shariat SF
    Eur Urol Focus; 2022 Jan; 8(1):239-252. PubMed ID: 33674256
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo.
    Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
    Low Urin Tract Symptoms; 2016 Sep; 8(3):150-8. PubMed ID: 27619779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The placebo effect in overactive bladder syndrome.
    Mangera A; Chapple CR; Kopp ZS; Plested M
    Nat Rev Urol; 2011 Jul; 8(9):495-503. PubMed ID: 21727941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.